Adult Dosing

Chronic asthma

• 20 mg NEB qid
• Note: Gradually decrease dosage to bid after patient is stabilized

Exercise-induced asthma

• 20 mg NEB 10-60 min before exercise or exposure to precipitating factor

Pediatric Dosing

Chronic asthma

• Children > 2 yrs: 20 mg NEB qid
• Note: Gradually decrease dosage to bid after patient is stabilized

Exercise-induced asthma

• 20 mg NEB 10-60min before exercise or exposure to precipitating factor
• Safety and effectiveness in children < 2 yrs have not been established

• Prophylactic agent for the management of bronchial asthma
• Exercise-induced bronchospasm or that induced by exposure to precipitating factors such as toluene diisocyanate, aspirin, cold air, sulfur dioxide and environmental pollutants

• Hypersensitivity to any of the ingredients of the product
• Acute asthma attack
• Status asthmaticus
• Arrhythmias

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Renal impairment: Dose adjustments not defined

• It is not indicated for the treatment of status asthmaticus
• Closely monitor for hypersensitivity reactions
• Therapy may produce cough or bronchospasm
• In patients who develop bronchospasm with cromolyn sodium use, administer bronchodilator prior to the administration
• Very severe bronchospasm has been reported with the administration of therapy
• Symptoms of asthma may recur if cromolyn sodium is reduced below the recommended dosage or discontinued
• Avoid mixing with other drugs in nebulizer as drug stability and safety have not been established
• To be used as directed by the physician. As it is a preventive medication, 4 weeks of continuous therapy may be required for optimum effects to be achieved
• Use a power-driven nebulizer with an adequate airflow rate, equipped with a suitable face mask or mouthpiece

Pregnancy Category:B

Breastfeeding: Safety unknown. Although no published data exist on the use of cromolyn during lactation, maternal milk levels are likely to be very low and it is expected to be poorly absorbed from the infant's gastrointestinal tract. An expert panel considers use of cromolyn to be acceptable during breastfeeding. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 3 December 2010).Manufacturer advises caution when administering to a nursing woman.

• RESP: Bronchospasm, transient cough, wheezing
• CNS: Dizziness, headache, drowsiness
• EENT: Throat irritation, dry throat, nasal congestion, sneezing, nasal itching, epistaxis, nasal burning
• GI: Nausea, bitter taste, stomachache
• HYPERSENSITIVITY: Anaphylaxis
• MISC: Serum sickness

• Mast cell stabilizer; inhibits mast cell degranulation; inhibits release of mediators from mast cells
• Absorption: Approximately 8% absorbed after inhalation
• Metabolism: None; CYP450: None
• Excretion: Rapidly excreted equally through urine and bile (Unchanged)
• Half-life: Unknown

US Trade Name(s)

• Only generic available

US Availability

cromolyn (generic)

• SOLN for INH: 10 mg/mL

Canadian Trade Name(s)

• Only generic available

Canadian Availability

cromolyn (generic)

• SOLN for INH: 1% (2mL sterules/polyneb)
• SOLN for INH: 10 mg/mL

UK Trade Name(s)

• Intal CFC-free Inhaler

UK Availability

Intal CFC-free Inhaler

• MDI: 5 mg/INH (112 actuations)

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Pulmonary

Mast Cell Stabilizers

Allergy & Immunology

Mast Cell Stabilizers